Mouse Anti-IgE Recombinant Antibody (clone 26A11) (CAT#: HPAB-AP104-YC)

Figure 1 shows the results of application of M1′ antibodies of the epitope group A2, including 1C11, 26A11, 51D2, 45C1) and epitope group B/C, including 26B11 and 28E9 without crosslinking.

Figure 2 shows IgE levels over time in response to NB infection with anti-IgE/M1′ and control antibodies.

Figure 3 show that anti-IgE/M1′ reduced serum IgE levels by 82-89% within four days of treatment.

Figure 4 show that anti-IgE/M1′ reduced serum IgE levels by 82-89% within four days of treatment.

Figure 5 illustrate the ability of the anti-IgE/M1′antibodies to therapeutically treat IgE response occurring late in an infection cycle to Nippostrongylus brasiliensis (“NB”) infection.

Figure 5A shows that peak IgE production occurred around day 15 and that all anti-IgE/M1′ antibodies reduced serum IgE. Figure 5B-5C shows that anti-IgE/M1′ antibody shows a significant reduction in both absolute and normalized IgE levels, respectively, relative to commencement of treatment.